Biocytogen 

Animal Models and Cell Lines

>Double Humanized Immune-Checkpoint Mice

B-hPD-1/hTIGIT mice


Basic characteristics

 1.png

 

Targeting strategy

image.png


Protein expression analysis

1.png

Fig 1. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hTIGIT mice were analyzed by flow cytometry. Mouse TIGIT+ T cells were detectable in the WT C57BL/6 mice, while human TIGIT+ T cells were detectable in the homozygous B-hPD-1/hTIGIT mice.


 

2.png

Fig 2. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hTIGIT mice were analyzed by flow cytometry. Mouse PD-1+ T cells were detectable in the WT C57BL/6 mice, while human PD-1+ T cells were detectable in the homozygous B-hPD-1/hTIGIT mice.


Combination Therapy of hTIGIT (Tiragolumab Analog) mAb and PD-1 mAb (Keytruda) (MC38 cell line)

image.png

Fig 3. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hTIGIT mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=6). Anti-hTIGIT antibody and the anti-hPD-1 antibody Keytruda shows obviously inhibitory effects respectively. Combination of anti-hTIGIT antibody and the anti-hPD-1 antibody Keytruda shows better inhibitory effects than single treatment, suggesting that B-hPD-1 /hTIGIT mouse is a powerful tool for in vivo evaluating combination therapy efficacy of hPD-1 antibodies and hTIGIT antibodies . (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

 

 

 

 

【Return list】
* Contact Name
* Quantity
Telephone No.
Email
* Shipping address
Verification code captcha

© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud